FranceMed Pharma is a privately owned British company, with solid base in the UK, since established in 1981. Active in Discovery/pioneering work in Ethical/OTC Discovery/R&D/Synthesis/Screening/Pre-Clinical/Clinical (Phase I, II and III), Manufacturing, Sales, Marketing and global licensing - with main strength in Discovery.
Its unique Ethical/OTC product range, developed over the last two decades, is widely available in the UK and some Export markets.
In the UK, its Class IIa Medical Device range is available from doctors via the NHS prescription re-imbursement scheme as well as pharmacies and major retailers.
FranceMed Pharma is certified to ISO 13485 and holds an EC Certificate.
FranceMed Pharma’s micro-fine sprays are patented, Discovery/World's First and employ Disruptive Unique Technology.
Commercially classified as Greenfield products with No Competition, No Me-Toos and No Generics. Clinically proven to work instantly and safely and to achieve long lasting effect, setting a new Gold Standard for treating various skin conditions.
Its Discovery “Instant T-CNS Signalling System”™ disruptive delivery technology allows a number of stimuli e.g. chemical, thermal and mechanical to be applied topically and simultaneously on the affected areas achieving greater efficacy than when applying each stimulus in turn. The efficacy is not just symptomatic as repeat use is clinically proven to treat the underlying condition with no side effects.